FC Capital
4
15M
3
1
0.25
- Areas of investment
Summary
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the FC Capital, startups are often financed by GoBeyond, Symbiosis Group, Shumway Capital. The meaningful sponsors for the fund in investment in the same round are Partners Investment, PPF Group, Symbiosis. In the next rounds fund is usually obtained by EASME - EU Executive Agency for SMEs.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in less than 2 deals per year. The important activity for fund was in 2019.
The fund has no exact preference in a number of founders of portfolio startups. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical, Business Development. Among the most popular portfolio startups of the fund, we may highlight Vedanta Biosciences, Cellestia Biotech.
Investments analytics
Analytics
- Total investments
- 4
- Lead investments
- 1
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (3)
- Health Care (2)
- Therapeutics (2)
- Biopharma (2)
- Medical (2) Show 3 more
- Investments by region
-
- Switzerland (2)
- United States (1)
- China (1)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Group Appearance index
- 1.00
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Harvest Integrated Research Organization | 18 Mar 2022 | Medical, Clinical Trials | Early Stage Venture | 1M | Shanghai, Shanghai, China |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.